发明名称 ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY
摘要 The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.
申请公布号 US2015183884(A1) 申请公布日期 2015.07.02
申请号 US201314142186 申请日期 2013.12.27
申请人 NATIONAL HEALTH RESEARCH INSTITUTES ;DEVELOPMENT CENTER FOR BIOTECHNOLOGY 发明人 Tsai Shih-Chong;Shih Neng-Yao;Yuan Ta-Tung;Liu Ko-Jiunn;Tseng Shih-Chi;Hu Chih-Yung;Wang Hsin-Yun;Chen Li-Tzong
分类号 C07K16/40;G01N33/574 主分类号 C07K16/40
代理机构 代理人
主权项 1. An antibody, or an scFv or Fab fragment thereof, comprising: one or more sequences selected from the group consisting of HCDR1 (GYTFTSCVMN; SEQ ID NO:3), HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO:4), HCDR3 (EGFYYGNFDN; SEQ ID NO:5), LCDR1 (RASENIYSYLT; SEQ ID NO:6), LCDR2 (NAKTLPE; SEQ ID NO:7), and LCDR3 (QHHYGTPYT; SEQ ID NO:8).
地址 MIAOLI COUNTY TW